CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

Current Drug Safety is a distinguished peer-reviewed journal published by Bentham Science Publishers, focusing on the critical intersection of pharmacology and toxicology. With an ISSN of 1574-8863 and an E-ISSN of 2212-3911, this journal serves as a platform for the latest research and advances in drug safety, highlighting the importance of pharmacological assessments and toxicity evaluations in therapeutic development and public health. Reaching a broad international audience from its base in the United Arab Emirates, Current Drug Safety offers an invaluable resource for researchers, professionals, and students interested in the dynamic fields of drug research and safety management. Despite a current Q3 categorization in multiple pharmacology and toxicology quartiles for 2023, the journal continues to strive for excellence in the scholarly community, reflecting its commitment to disseminating high-quality research. While not operating under an open access model, articles can be accessed through institutional subscriptions and other platforms, ensuring valuable insights into drug safety are available to those who need it most.

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

Welcome to Pulmonary Pharmacology & Therapeutics, a leading journal dedicated to the dissemination of innovative research and insights in the fields of pulmonary medicine and pharmacology. Published by Academic Press Ltd - Elsevier Science Ltd, this journal has made significant contributions to the academic community since its inception in 1997, with an ongoing commitment to relevant advancements projected through to 2024. With reputable Q2 rankings across vital categories including Biochemistry (medical), Medicine (miscellaneous), Pharmacology (medical), and Pulmonary and Respiratory Medicine, Pulmonary Pharmacology & Therapeutics is ranked in the top tier of its field, reflecting its impact on the discipline as evidenced by its Scopus rankings. Researchers, healthcare professionals, and students alike can access a wealth of high-quality articles that address the complexity of pulmonary diseases and therapeutic strategies, supporting research and clinical practice alike. Join the vibrant community contributing to this essential field and explore the latest findings that can drive change in patient care and therapeutic effectiveness.

CLINICAL DRUG INVESTIGATION is a prestigious journal dedicated to the fields of Medicine and Pharmacology, published by ADIS INT LTD in the United Kingdom. With an ISSN of 1173-2563 and an E-ISSN of 1179-1918, this journal has been a crucial contributor to the scientific community since its inception in 1995. Recognized for its significant impact, it holds a commendable Q2 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories, placing it firmly in the 70th percentile within its field. Researchers, professionals, and students alike benefit from its commitment to publishing innovative studies and comprehensive reviews that advance understanding and application of clinical drugs. Although it does not currently offer open access options, its rigorous peer-review process ensures the integrity and quality of published articles. The journal's scope encompasses a wide range of topics related to drug investigation, making it an essential resource for anyone involved in medical research and pharmacological practice.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, an esteemed publication in the field of pharmacology, is published by Wiley-Hindawi and has been at the forefront of clinical research since its inception in 1976. Operating primarily from the United Kingdom, this journal features a diverse array of articles that encompass both fundamental and practical aspects of clinical pharmacy, thereby supporting the advancement of therapeutic practices. With an ISSN of 0269-4727 and an E-ISSN of 1365-2710, it is indexed in key databases and holds respectable ranks within its categories; achieving Q3 in Pharmacology and Q2 in Medical Pharmacology in the latest quartile rankings. Its Scopus ranking reflects both its quality and relevance, being positioned in the 55th percentile for medical pharmacology and the 45th for pharmacology, toxicology, and pharmaceutics. Although it does not currently operate under an Open Access model, the journal's extensive readership and rigorous peer-review process ensure that the latest research reaches practitioners and academics alike. With a commitment to bridging the gap between pharmacological science and clinical practice, the JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS remains a critical resource for professionals striving to enhance patient outcomes through informed medication management.

ANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.

PHARMACOTHERAPY, an esteemed journal published by WILEY, stands as a pivotal resource within the field of medical pharmacology. With its ISSN 0277-0008 and E-ISSN 1875-9114, this journal has been at the forefront of pharmacological research since its inception in 1981. Renowned for its rigorous peer-review process and impactful contributions, it currently holds a prestigious Q1 quartile ranking in the pharmacology category, underscoring its significance as a leading publication in the field. It ranks #40 out of 272 journals in Scopus, placing it in the top 15% percentile of its category. While not an open-access publication, PHARMACOTHERAPY remains committed to advancing knowledge and understanding in pharmacological sciences, making it an indispensable resource for researchers, healthcare professionals, and students dedicated to improving therapeutic outcomes and drug utilization. Based in the United States, at 111 River St, Hoboken, NJ, the journal is poised to continue its impact through to 2024 and beyond, welcoming contributions that further the discourse in pharmacotherapy.

JAMA Internal Medicine is a premier scholarly journal published by the American Medical Association, renowned for its rigorous peer-review process and commitment to advancing the field of internal medicine. With an impressive impact factor that positions it in the upper echelon of medical journals, specifically ranked at Q1 in Internal Medicine and holding a remarkable Scopus rank of #2 out of 167, the journal provides a vital platform for original research, reviews, and enlightening discussions that shape clinical practices and policies. As an accessible repository of cutting-edge findings and comprehensive analyses, JAMA Internal Medicine offers both subscription and open access options, ensuring that the latest developments in medicine are available to clinicians, researchers, and the academic community at large. With its focus spanning from 2013 to 2024 and its dedication to high-quality scholarship, the journal serves as an essential resource for those seeking to enhance their understanding of the complexities of internal medicine and improve patient care.